This is a preview of subscription content, log in via an institution to check access.
Reference
Lin J, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. 55th Annual Meeting of the American Society of Clinical Oncology : abstr. 7561, 31 May 2019. Available from: URL: http://abstracts.asco.org/239/AbstView_239_271705.html
Rights and permissions
About this article
Cite this article
Assessing cost effectiveness of CAR-T therapy in B-cell lymphoma. PharmacoEcon Outcomes News 831, 6 (2019). https://doi.org/10.1007/s40274-019-5994-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5994-3